How Are Authorized Representative Responsibilities Divided for Overseas Registration of Implantable Products?

When registering implantable products overseas, the division of responsibilities for the authorized representative should be based on the target country's regulations. First confirm the product classification and registration pathway, then clarify the roles of the applicant, certificate holder, and local agent. Entering GHWP member states or other emerging markets should not simply replicate the CE registration model; assess the degree of technical documentation reuse and complete local language conversion of labels and instructions as required. An authorized representative typically handles communications with regulators, maintains technical files, receives post-market surveillance requirements, and assists with adverse event reporting — but does not assume legal responsibility for product quality and safety. Enterprises should prepare authorization letters, agency agreements, quality system certificates, risk management and clinical evaluation evidence, and explicitly define change, renewal, withdrawal notification, and certificate control rights in the agreement.

Key Summary

The division of responsibilities for the authorized representative in overseas registration of implantable devices must be based on the laws and regulations of the target country. Confirm product classification and registration route, and assign clear roles among the applicant, certificate holder, and local agent. When entering GHWP member states or other emerging markets, do not simply copy the CE registration model. Evaluate the reusability of technical documents and complete localization of labels and instructions for use. The authorized representative is normally responsible for communicating with regulatory authorities, maintaining technical files, receiving post-market surveillance requirements, and supporting adverse event reporting, but the legal responsibility for product quality and safety remains with the manufacturer.

Applicable Scenarios and Core Issues

This article applies to implantable products such as bone screws, cardiac stents, artificial joints, absorbable sutures, and interventional consumables registering in the EU, GHWP member states, Southeast Asia, the Middle East, Latin America, and other markets. Due to the high risk of implantable products, most countries require a locally established legal person or entity to act as an authorized representative or local agent. The core issue is not whether an authorized representative is mandatory, but what responsibilities the representative assumes and what responsibilities the enterprise retains.

Common misconceptions include treating the authorized representative as the registration applicant, transferring all certificate holder obligations to the agent, ignoring post-market surveillance duties, and losing the registration certificate when replacing the representative. These issues are amplified for implantable devices because they require continuous follow-up, device tracking, clinical data collection, and stricter post-market requirements.

Registration Judgment Logic

Step 1: Confirm Product Classification

Verify whether the product is within the medical device regulatory scope in the target country and determine its risk class. For example, bone screws, cardiac stents, artificial joints, and absorbable sutures may have different risk classifications across countries. Consult the target country's classification guidance rather than directly adopting CE classification.

Step 2: Confirm Registration Pathway and Applicant

Some countries require the overseas manufacturer to appoint a locally registered entity as the applicant. In such cases, the representative may be listed as the applicant, but the manufacturer remains the actual producer responsible for the product. Distinguish among the roles of applicant, registration certificate holder, and manufacturer.

Step 3: Assess Documentation Reuse

If the enterprise already holds an NMPA registration, CE certificate, or FDA 510(k)/PMA, conduct a gap analysis between the existing technical files, quality management system, clinical evaluation, labels, and the target country's requirements. Implantable devices require high-level evidence for materials, sterilization, biocompatibility, and clinical safety; simple translation is not sufficient.

Step 4: Confirm Local Agent and Authorized Representative Duties

In many GHWP member states, Southeast Asian and Middle Eastern countries, a local agent or contact person must be appointed to hold the certificate, liaise with regulators, receive inspections, and handle adverse events. Evaluate whether the agent has the capability to handle implantable devices and specify all obligations, notification timeframes, and termination terms in the agreement.

Step 5: Confirm Post-Market Maintenance Requirements

Implantable products often require post-market clinical follow-up, implant registries, product traceability, and updated clinical evaluations. The authorized representative must be able to cooperate with these requirements; otherwise, the certificate could be suspended.

Documentation and Evidence

Prepare a file package directly related to the responsibility division:

• Authorization letter and local agency agreement: define the scope of authorization, validity period, termination conditions, certificate control rights, and change process.
• Technical file for the target country: product description, intended use, design verification, materials, sterilization, stability, packaging, and other data reformatted per target country requirements.
• Risk management report: ISO 14971 or equivalent; for implantables include biological, surgical, and long-term implantation risks.
• Clinical evaluation evidence: clinical literature, clinical trial reports, and post-market clinical follow-up data. Additional local data may be needed if the target country has specific ethnic or epidemiological requirements.
• Quality management system certificate: ISO 13485 is the basic requirement; some countries require MDSAP or on-site inspection.
• Labels and instructions for use: language, warnings, follow-up intervals, MRI compatibility, implant card, and other local requirements.
• Post-market surveillance documents: adverse event reporting process, product tracking mechanism, and periodic safety update report arrangement.

Common Errors

• Misconception 1: Treating the authorized representative as an entity that can directly replace the manufacturer in assuming full quality responsibility. In most jurisdictions, product safety liability rests with the manufacturer.
• Misconception 2: Selecting a local agent that lacks experience with implantable devices. Some agents only handle ordinary consumables and do not understand follow-up, traceability, or adverse event escalation, leading to ineffective post-market oversight.
• Misconception 3: Failing to stipulate certificate control rights in the agency agreement. If the agent changes during registration, it may withhold the certificate or delay cooperation, halting product sales.
• Misconception 4: Ignoring change and renewal responsibilities. Clarify whether the authorized representative must submit a new application or file change notifications for product design, manufacturing site, materials, or sterilization method changes.
• Misconception 5: Directly translating all documents without localization. Clinical data, instructions, and warnings may be interpreted differently across cultures and affect safety.
• Misconception 6: Allowing post-market surveillance and adverse event reporting to become an orphan obligation. The manufacturer may think the agent will handle it, and the agent may think the manufacturer remains responsible, resulting in no reports.

Enterprise Preparation Checklist

• Confirmed the target country's regulatory scope, classification, and registration pathway using official guidance or a specialized regulatory service provider.
• Established a project team for the target country with members from regulatory affairs, R&D, clinical, quality, and sales.
• Completed a gap table between existing technical files and the target country's requirements, distinguishing reusable documents from those requiring localization.
• Assessed the qualifications of the local agent/authorized representative, including previous registration experience, implantable device capability, and regulatory contact channels.
• Signed an authorization agreement clearly defining responsibilities, certificate ownership, change notification timeframes, adverse event reporting processes, and termination clauses.
• Prepared the quality management system certificate, risk management report, clinical evaluation documentation, and localized versions of labels and instructions.
• Designed a post-market surveillance plan, including product traceability, customer complaints, adverse event reporting, and periodic safety reports.
• Planned certificate maintenance costs, including agency annual fees, renewal fees, system audits, and possible on-site inspection fees.

AIMEILI's View

The most common misjudgment is to treat the authorized representative as an agent that handles everything or, conversely, to transfer all responsibility to the representative. The correct approach is to define the legal relationships among the registration applicant, certificate holder, and manufacturer at the beginning of the project, and then select a local agent according to the target country's requirements.

Prioritize a registration gap assessment early in the project. Once the target country is confirmed, take three weeks to compare that country's regulatory framework, classification directory, and submission format to evaluate how much existing CE/NMPA/FDA documentation can be reused. Implantable device differences usually appear in clinical evaluation, labeling, and follow-up requirements; if these are missed, the correction cycle can be very long.

Reusable documentation typically includes basic design verification, material properties, EMC and basic safety, and ISO 13485 system files. Documentation that must be localized includes instructions for use, patient labels, registration-specific technical files, and clinical evidence containing local epidemiological data and physician practice preferences.

Do not choose a local agent or authorized representative based only on price and registration success rate. Investigate its post-market surveillance capability for implantable products. Certificate control rights, change and renewal clauses must be written into the agreement, including how certificates and files will be returned or transferred if the agent merges, closes, or transfers its business.

For multi-country registration, establish a unified document list, gap table, and registration plan. This minimizes recompiling documents for each country and allows quick identification of evidence when regulators request corrections.

Common Follow-Up Questions

Can the authorized representative be changed?

Yes, but you must follow the target country's regulatory change procedure. Usually, the new authorized representative submits a change application and provides the old representative's consent or legal documents. Products cannot be sold until the certificate change is completed.

Who ultimately holds the registration certificate?

Regulations vary by country. Some allow the manufacturer to be the certificate holder, while others require a local agent to hold it. Regardless of ownership, the manufacturer remains the quality responsible entity. The agreement should specify certificate ownership and delivery conditions.

Is the authorized representative responsible for product quality?

Generally, the authorized representative is not responsible for product design or manufacturing quality, but may bear administrative liability for failing to fulfill regulatory communication or adverse event reporting obligations. If the representative makes false statements in registration documents, it may be subject to legal liability.

Who reports adverse events?

The manufacturer is typically responsible for submitting adverse event reports to the target country's regulatory authority. The authorized representative or local agent is usually responsible for initial receipt, translation, forwarding, and deadline reminders. The agreement should specify whether reporting must occur within 48 or 72 hours, and who will complete the initial report.

Continue Reading

• How to Choose a Local Agent for Overseas Registration of Implantable Products
• How Are Authorized Representative Responsibilities Divided for Laboratory Equipment Overseas Registration?
• How Are Authorized Representative Responsibilities Divided for Sterile Consumables Overseas Registration?
• How to Conduct Post-Market Surveillance for Laboratory Equipment Overseas Registration?

Published: 2026-08-30 09:15 | Updated: 2026-08-30 09:15

Content source: AIMEILI Regulatory Editorial Department. Professional review: AIMEILI Medical Device International Registration Project Team. Information is based on official regulatory bodies, international organizations, standard organizations, and public regulatory information; industry media and project experience are used as supplementary judgment. This article is for preliminary understanding, document preparation, and project planning, and does not replace the official requirements of the target country's regulatory authority, test conclusions, or legal advice.